Alpha-synuclein: Difference between revisions

Joel L. Sussman (talk | contribs)
No edit summary
No edit summary
Line 1: Line 1:
<StructureSection load='6flt' size='340' side='right' caption='Human alpha-synuclein (PDB [[6flt]])' scene=''>
<StructureSection load='6flt' size='340' side='right' caption='Human alpha-synuclein (PDB [[6flt]])' scene='84/840509/Cv/1'>


== Function ==
== Function ==


'''Alpha-Synuclein''' (Syn) is a human neuronal protein which has several roles in synaptic activity. Syn enhances vesicle priming, fusion and dilation of exocytotic pores<ref>PMID:28288128</ref>.  Syn acts as a molecular chaperone in assisting the folding of SNAREs - the synaptic fusion components<ref>PMID:20798282</ref>. Syn associates with the dopamine transporter and modulates its activity<ref>PMID:26442590</ref>.
'''Alpha-Synuclein''' (Syn) is a human neuronal protein which has several roles in synaptic activity. Syn enhances vesicle priming, fusion and dilation of exocytotic pores<ref>PMID:28288128</ref>.  Syn acts as a molecular chaperone in assisting the folding of SNAREs - the synaptic fusion components<ref>PMID:20798282</ref>. Syn associates with the dopamine transporter and modulates its activity<ref>PMID:26442590</ref>.


== Disease ==
== Disease ==
Line 15: Line 15:
== Structural highlights ==
== Structural highlights ==


The Syn structure shows 8 β-sheet forming segments interrupted by Gly residues.  Seven PD-associated familial mutations are known. The 3D structure shows a hydrophobic cleft which can provide an entry point for an incoming Syn molecule elongating the fibril<ref>PMID:29969391</ref>.
The Syn structure shows 8 β-sheet forming segments interrupted by Gly residues.  Seven PD-associated familial mutations are known. The 3D structure shows a hydrophobic cleft which can provide an entry point for an incoming Syn molecule elongating the fibril<ref>PMID:29969391</ref>.


</StructureSection>
</StructureSection>

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

Michal Harel, Joel L. Sussman, Alexander Berchansky